BC022651 Activators
BC022651 Activators encompass a diverse array of chemical compounds that enhance the functional activity of BC022651 through distinct signaling pathways and molecular mechanisms. Forskolin, by elevating cellular cAMP, indirectly boosts BC022651 activity via PKA-dependent phosphorylation processes. Similarly, PMA activates PKC, which could phosphorylate and activate BC022651 or related proteins. Sphingosine-1-phosphate, a lipid mediator, might engage specific receptors to initiate signaling cascades involving BC022651, thus enhancing its function. IBMX, by inhibiting phosphodiesterases, maintains elevated cAMP levels, potentially activating PKA and influencing BC022651 activity.
Akt Activators are a collection of chemical compounds that enhance the activity of Akt through various mechanisms, primarily by influencing the PI3K/Akt signaling pathway. Insulin and IGF-1 are well-known activators that bind to their respective receptors and initiate a cascade of phosphorylation events culminating in the activation of Akt. Compounds such as LY294002, while typically used as PI3K inhibitors, can elicit a paradoxical activation of Akt through complex feedback mechanisms within the PI3K/Akt/mTOR pathway. SC79 directly interacts with Akt to facilitate its membrane translocation and subsequent activation. Vanadium compounds like vanadyl sulfate mimic insulin's action and activate Akt via the PI3K pathway, while AICAR can activate AMPK, which may subsequently phosphorylate and enhance the activity of Akt.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC). PKC activation could lead to phosphorylation events that enhance the functional activity of BC022651 if BC022651 is part of a pathway regulated by PKC. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
This lipid signaling molecule activates sphingosine-1-phosphate receptors, leading to downstream activation of pathways that could include BC022651, thereby potentially enhancing its activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP levels, which could activate PKA and therefore enhance the functional activity of BC022651 through phosphorylation if it is involved in cAMP/PKA signaling pathways. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
W-7 is a calmodulin antagonist. By inhibiting calmodulin, it may affect calcium-signaling pathways, potentially leading to enhanced activity of BC022651 if it is part of or regulated by calcium/calmodulin-dependent processes. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that also activates stress-activated protein kinases like JNK. Activation of such kinases could modify the activity of BC022651 if it is regulated by stress response pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated protein kinase), which may lead to changes in the actin cytoskeleton and related signaling pathways. If BC022651 is part of these pathways, its activity could be enhanced. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentration. This increase could activate calcium-dependent kinases or phosphatases, potentially enhancing the activity of BC022651 if it is calcium-dependent. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it may alter signaling pathways downstream of PI3K, such as the Akt pathway, which could lead to changes in the activity of BC022651 if it is part of or regulated by these pathways. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A. Inhibition of these phosphatases can lead to increased phosphorylation levels of proteins, which could enhance the functional activity of BC022651 if it is regulated by phosphorylation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a potent antioxidant and has been shown to inhibit multiple protein kinases. If BC022651's activity is regulated by kinases that are sensitive to EGCG, this compound could enhance the activity of BC022651 through this mechanism. | ||||||